Loriot Y - Search Results

1

Systemic treatments for high-risk localized prostate cancer.

Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D. Pignot G, et al. Among authors: loriot y. Nat Rev Urol. 2018 Aug;15(8):498-510. doi: 10.1038/s41585-018-0017-x. Nat Rev Urol. 2018. PMID: 29765147 Review.

2

[Management of localized germ-cell tumours of the testis].

Loriot Y, Fizazi K. Loriot Y, et al. Rev Prat. 2007 Feb 28;57(4):379-84. Rev Prat. 2007. PMID: 17455739 Review. French.

3

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Loriot Y, et al. Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.

4

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K. Loriot Y, et al. Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17. Eur J Cancer. 2010. PMID: 20483588

5

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

Loriot Y, Massard C, Fizazi K. Loriot Y, et al. Ann Oncol. 2012 May;23(5):1085-1094. doi: 10.1093/annonc/mdr573. Epub 2012 Jan 20. Ann Oncol. 2012. PMID: 22267211 Free article. Review.

6

Towards random sequencing or precision medicine in castration-resistant prostate cancer?

Loriot Y, Fizazi K. Loriot Y, et al. Eur Urol. 2014 Jan;65(1):37-8. doi: 10.1016/j.eururo.2013.09.019. Epub 2013 Sep 19. Eur Urol. 2014. PMID: 24075577 No abstract available.

7

One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?

Loriot Y, Massard C, Fizazi K. Loriot Y, et al. Eur Urol. 2014 Oct;66(4):653-4. doi: 10.1016/j.eururo.2014.03.024. Epub 2014 Mar 31. Eur Urol. 2014. PMID: 24735730 No abstract available.

8

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y. Al Nakouzi N, et al. Among authors: loriot y. Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2. Eur Urol. 2015. PMID: 24837187

9

Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.

Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Montgomery B, et al. Among authors: loriot y. Eur Urol. 2015 May;67(5):866-73. doi: 10.1016/j.eururo.2014.06.042. Epub 2014 Jul 10. Eur Urol. 2015. PMID: 25018037 Clinical Trial.

10

Who dies from prostate cancer?

Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, Di Palma M, Escudier B, Fizazi K. Patrikidou A, et al. Among authors: loriot y. Prostate Cancer Prostatic Dis. 2014 Dec;17(4):348-52. doi: 10.1038/pcan.2014.35. Epub 2014 Oct 14. Prostate Cancer Prostatic Dis. 2014. PMID: 25311767

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page